<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00549523</url>
  </required_header>
  <id_info>
    <org_study_id>U19AT003264-01</org_study_id>
    <secondary_id>U19AT003264-01</secondary_id>
    <secondary_id>TICIPS002_RP01 (E295/05)</secondary_id>
    <nct_id>NCT00549523</nct_id>
  </id_info>
  <brief_title>A Controlled Study of the Safety and Efficacy of Lessertia Frutescens in HIV-infected South African Adults</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of Lessertia Frutescens (L.)Goldblatt and J.C. Manning (Syn. Sutherlandia Frutescens (L.)R. Br.)in HIV-infected South African Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a 2-stage, double-blind, randomized, placebo-controlled study in which fifty-six&#xD;
      HIV-positive subjects will be randomized into the first stage. Interim analysis to determine&#xD;
      continuation to stage 2 will be performed to determine continuation after 8 subjects per arm&#xD;
      have completed a 24-week dosing regimen.&#xD;
&#xD;
      Primary objectives are to determine the safety of Lessertia frutescens when used by HIV-1&#xD;
      infected adults with early disease, and to document the impact of Lessertia frutescens on&#xD;
      markers of HIV disease progression. Secondary objective is to determine the effect of&#xD;
      Lessertia frutescens on quality of life in HIV-infected adults and length of infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a 2-stage, double-blind, randomized, placebo-controlled study following a&#xD;
      two-stage, statistical selection theory design. Fifty-six HIV positive subjects will be&#xD;
      randomized onto Stage 1 that will comprise a 4-arm parallel group (one placebo and 3&#xD;
      treatment groups) trial. One or possibly two interim analyses will be performed to determine&#xD;
      continuation to Stage 2. A blinded interim analysis to determine the superior active&#xD;
      treatment arm of Stage 1 will be continued to Stage 2 after 8 subjects per arm have completed&#xD;
      the 24-week dosing regimen and the interim analysis. The study will be terminated if the&#xD;
      interim analysis identifies either significant safety issues, or demonstrable&#xD;
      non-significance. Following a significant outcome in the blinded interim analysis, the&#xD;
      selected active and placebo control arms will continue blinded until total n=48 participants&#xD;
      per arm for the placebo and selected treatment group have completed 24 weeks per arm.&#xD;
      Respective groups will receive capsules containing L. frutescens in dosages of 0 (placebo&#xD;
      material), 400mg bid, 800 mg bid or 1200 mg bid in the first stage. Progression to stage 2&#xD;
      will utilize a two arm design in which 34 subjects will receive either 0 mg L. frutescens&#xD;
      (placebo) or the active dosage of L. frutescens bid for 24 weeks.&#xD;
&#xD;
      Primary objectives are to determine the safety of Lessertia frutescens when used by HIV-1&#xD;
      infected adults with early disease, and to document the impact of Lessertia frutescens on&#xD;
      markers of HIV disease progression. Secondary objective is to determine the effect of&#xD;
      Lessertia frutescens on quality of life in HIV-infected adults and length of infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary: determine safety of L. frutescens when used by HIV-1 infected adults with early disease, and to document disease progression.</measure>
    <time_frame>24 week treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary: Determine the effect of L. frutescens on quality of life in HIV-1 infected adults, and length of infection.</measure>
    <time_frame>24 week treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (capsule filled with inert materials)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg bid Lessertia Frutescens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg bid Lessertia Frutescens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200 bid Lessertia Frutescens</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules containing 0 mg bid (placebo)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose</intervention_name>
    <description>Capsules containing 400 mg bid of L. frutescens.</description>
    <arm_group_label>Low Dose</arm_group_label>
    <other_name>Lessertia Frutescens</other_name>
    <other_name>Sutherlandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mid Dose</intervention_name>
    <description>Capsules containing 800 mg bid of L. frutescens.</description>
    <arm_group_label>Mid Dose</arm_group_label>
    <other_name>Lessertia Frutescens</other_name>
    <other_name>Sutherlandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose</intervention_name>
    <description>Capsules containing 1200 mg bid of L. frutescens.</description>
    <arm_group_label>High Dose</arm_group_label>
    <other_name>Lessertia Frutescens</other_name>
    <other_name>Sutherlandia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 21 - 65 years&#xD;
&#xD;
          -  HIV-1 infection documented by two different rapid tests for HIV-1 antibodies&#xD;
&#xD;
          -  CD4 count &gt;350 cells/ul&#xD;
&#xD;
          -  Viral load&lt; 20,000 copies/mL&#xD;
&#xD;
          -  Normal hematological function&#xD;
&#xD;
          -  Absence of clinically significant renal disease&#xD;
&#xD;
          -  Normal liver function&#xD;
&#xD;
          -  Random glucose &lt; 11.1 mmol/L&#xD;
&#xD;
          -  Normal electrocardiogram&#xD;
&#xD;
          -  Regular attendance at the Wellness Clinic for at least 4 visits&#xD;
&#xD;
          -  Cognitive capacity sufficient to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any AIDS-defining diagnosis&#xD;
&#xD;
          -  Weight loss &gt; 5% of body weight within the preceding six months&#xD;
&#xD;
          -  Other features of undiagnosed tuberculosis (including cough, fatigue, drenching night&#xD;
             sweats and abnormal chest radiograph)&#xD;
&#xD;
          -  Any other significant disease (active TB, hypertension, diabetes mellitus and other&#xD;
             endocrine disorders, peptic ulcer disease, gastrointestinal malabsorption, psychiatric&#xD;
             illness) either newly diagnosed or controlled by medication.&#xD;
&#xD;
          -  Use of any allopathic or traditional medicine other than isoniazid for TB prophylaxis.&#xD;
&#xD;
          -  Prior or current use of antiretroviral therapy&#xD;
&#xD;
          -  History of allergic conditions or drug allergy/hypersensitivity&#xD;
&#xD;
          -  Either history or family history of autoimmune disease&#xD;
&#xD;
          -  Alcohol use of &gt;7 units per week or &gt;3 per session, tobacco use of more than 10&#xD;
             cigarettes per day or description of recreational drug use within the past 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Folk, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, Edendale Hospital, Pvt Bag X 509</name>
      <address>
        <city>Pietermaritzburg</city>
        <zip>3216</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <reference>
    <citation>Johnson Q, Syce J, Nell H, Rudeen K, Folk WR. A randomized, double-blind, placebo-controlled trial of Lessertia frutescens in healthy adults. PLoS Clin Trials. 2007 Apr 27;2(4):e16.</citation>
    <PMID>17476314</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 24, 2007</study_first_submitted>
  <study_first_submitted_qc>October 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2007</study_first_posted>
  <last_update_submitted>October 7, 2016</last_update_submitted>
  <last_update_submitted_qc>October 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Alternative Medicine</keyword>
  <keyword>Complementary Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

